Previous close | 243.22 |
Open | 239.39 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1000 |
Day's range | 237.89 - 248.54 |
52-week range | 208.35 - 526.00 |
Volume | |
Avg. volume | 965,922 |
Market cap | 37.482B |
Beta (5Y monthly) | 0.93 |
PE ratio (TTM) | 39.26 |
EPS (TTM) | 6.11 |
Earnings date | 25 Apr 2022 - 29 Apr 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 371.38 |
Illumina (ILMN) subsidiary GRAIL's MCED blood test will be offered along with existing single cancer screenings to advance cancer care delivery through early detection.
MENLO PARK, Calif. & SALT LAKE CITY, May 17, 2022--Intermountain Healthcare will offer Galleri®, GRAIL's multi-cancer early detection blood test, as a complement to existing single cancer screenings.
With its stock down 31% over the past month, it is easy to disregard Illumina (NASDAQ:ILMN). We, however decided to...